Research-grade Proteins Market Size, Share & Trends Analysis Report By Product (Cytokines & Growth Factors, Antibodies, Immune Checkpoint Proteins), By Host Cell (Mammalian Cells, Bacterial Cells), By End-use, By Region, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 2 Business Days
Research-grade Proteins Market Growth & Trends
The global research-grade proteins market size is anticipated t%li%reach USD 1.75 billion by 2030, according t%li%a new report by Grand View Research, Inc. The market is projected t%li%grow at a CAGR of 11.49% from 2025 t%li%2030. The growing investments in research and development within the fields of cancer research and rising demand for personalized medicines are anticipated t%li%contribute t%li%the growth of the market. In addition, the rising government investments in numerous countries for various clinical studies are expected t%li%drive the growth of the market. Moreover, the growing advancements in the biotechnology industry in developing countries are further driving the growth of the market over the forecast period.
The COVID-19 pandemic positively impacted the market due t%li%the surge in research activities for developing vaccines, diagnostics, and therapeutics. As regulatory authorities focused on expediting the approval processes for vaccine candidates, the demand for contract manufacturing increased. Although novel vaccine platforms, such as mRNA vaccines, received significant attention, several recombinant protein vaccine alternatives were als%li%being evaluated. For instance, in July 2022, Novavax, Inc.’s Nuvaxovid (NVX-CoV2373) recombinant protein-based COVID-19 vaccine received an expanded conditional marketing authorization for use in the EU. Furthermore, the pandemic highlighted the need for agile and flexible manufacturing abilities in biologics. This factor is expected t%li%boost the competitive landscape and fuel market growth in the near future.
As per Global Genes, in October 2019, more than 400 million people globally are living with rare and genetic diseases. This figure indicates the dire need for treatments and the betterment of clinical settings as well as health awareness. The need for advanced research and drug targeting mechanisms knowledge is crucial for medicine development. Many regions have developed biobanks from cohort programs t%li%provide researchers with high-quality samples for revolutionizing treatment efforts. This is expected t%li%result in an increased focus on biomarkers discovery for various conditions. Thus, initiatives and government interest in research activities for building a better healthcare infrastructure are expected t%li%enhance the applications of research-grade proteins, consequently driving market growth.
However, protein production is a time-consuming activity, which often requires high maintenance of the operating conditions during the procedure. Even with the high and ever-increasing demand for these recombinant products, support from regulatory bodies is still evolving at a slower pace. Research-grade proteins are usually manufactured via a host or an expression system, where the gene specific t%li%the desired product is expressed through stages of transfection and bacterial transformation or viral transduction. This complex process often has the disadvantage of over-expression of untargeted regions and even utilizes more time. Thus, the absence of specific guidelines and regulations for recombinant technology is a major factor hindering the booming market of research-grade proteins.
Research-grade Proteins Market Report Highlights
Research-grade Proteins Market Growth & Trends
The global research-grade proteins market size is anticipated t%li%reach USD 1.75 billion by 2030, according t%li%a new report by Grand View Research, Inc. The market is projected t%li%grow at a CAGR of 11.49% from 2025 t%li%2030. The growing investments in research and development within the fields of cancer research and rising demand for personalized medicines are anticipated t%li%contribute t%li%the growth of the market. In addition, the rising government investments in numerous countries for various clinical studies are expected t%li%drive the growth of the market. Moreover, the growing advancements in the biotechnology industry in developing countries are further driving the growth of the market over the forecast period.
The COVID-19 pandemic positively impacted the market due t%li%the surge in research activities for developing vaccines, diagnostics, and therapeutics. As regulatory authorities focused on expediting the approval processes for vaccine candidates, the demand for contract manufacturing increased. Although novel vaccine platforms, such as mRNA vaccines, received significant attention, several recombinant protein vaccine alternatives were als%li%being evaluated. For instance, in July 2022, Novavax, Inc.’s Nuvaxovid (NVX-CoV2373) recombinant protein-based COVID-19 vaccine received an expanded conditional marketing authorization for use in the EU. Furthermore, the pandemic highlighted the need for agile and flexible manufacturing abilities in biologics. This factor is expected t%li%boost the competitive landscape and fuel market growth in the near future.
As per Global Genes, in October 2019, more than 400 million people globally are living with rare and genetic diseases. This figure indicates the dire need for treatments and the betterment of clinical settings as well as health awareness. The need for advanced research and drug targeting mechanisms knowledge is crucial for medicine development. Many regions have developed biobanks from cohort programs t%li%provide researchers with high-quality samples for revolutionizing treatment efforts. This is expected t%li%result in an increased focus on biomarkers discovery for various conditions. Thus, initiatives and government interest in research activities for building a better healthcare infrastructure are expected t%li%enhance the applications of research-grade proteins, consequently driving market growth.
However, protein production is a time-consuming activity, which often requires high maintenance of the operating conditions during the procedure. Even with the high and ever-increasing demand for these recombinant products, support from regulatory bodies is still evolving at a slower pace. Research-grade proteins are usually manufactured via a host or an expression system, where the gene specific t%li%the desired product is expressed through stages of transfection and bacterial transformation or viral transduction. This complex process often has the disadvantage of over-expression of untargeted regions and even utilizes more time. Thus, the absence of specific guidelines and regulations for recombinant technology is a major factor hindering the booming market of research-grade proteins.
Research-grade Proteins Market Report Highlights
- Based on product, the cytokines & growth factors segment dominated the market with the largest revenue share of 23.61% in 2024 and the segment is anticipated t%li%grow with the fastest CAGR of 17.62% over the forecast period. This can be attributed t%li%its role in various clinical studies for drug discovery and development
- Based on host cell, the mammalian cells segment dominated the market with the largest revenue share of 55.73% in 2024. The large share is primarily due t%li%its similar biological makeup t%li%human cells, which helps in the production of biopharmaceuticals, including monoclonal antibodies, vaccines, and many more
- Based on end-use, the pharmaceutical & biotechnology companies segment held the largest market share of 61.48% in 2024. Due t%li%the increasing number of research activities for drug discoveries & development and the growing demand for personalized medicines, the demand for research-grade proteins is projected t%li%boost over the forecast period
- Based on region, North America dominated the market with a revenue share of 44.47% in 2024. This large share is attributed t%li%the presence of major market players and robust healthcare infrastructure. These factors are anticipated t%li%boost the market for research-grade proteins in the region over the forecast period
CHAPTER 1. RESEARCH-GRADE PROTEINS MARKET: METHODOLOGY AND SCOPE
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Product Segment
1.2.2. Host Cell Segment
1.2.3. End Use Segment
1.3. Research Assumptions
1.4. Information Procurement
1.4.1. Primary Research
1.5. Information or Data Analysis
1.6. Market Formulation & Validation
1.7. Market Model
1.8. Global Market: CAGR Calculation
1.9. Objectives
CHAPTER 2. RESEARCH-GRADE PROTEINS MARKET: EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. RESEARCH-GRADE PROTEINS MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.1.1. Increasing use of recombinant proteins in research activities
3.3.1.2. Growing research activities for drug discovery and precision medicine
3.3.1.3. Rising adoption of biologics & biosimilars
3.3.2. Market Restraint Analysis
3.3.2.1. Regulatory and safety concerns regarding protein production
3.3.2.2. Dearth of skilled personnel and expertise
3.4. Business Environment Analysis
3.4.1. PESTEL Analysis
3.4.2. Porter’s Five Forces Analysis
3.4.3. COVID-19 Impact Analysis
CHAPTER 4. PRODUCT BUSINESS ANALYSIS
4.1. Product Segment Dashboard
4.2. Research-grade Proteins Market: Product Movement Analysis
4.3. Global Research-Grade Proteins Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.4. Cytokines & Growth Factors
4.4.1. Cytokines & Growth Factors Market, 2018 - 2030 (USD Million)
4.4.2. Interferons (IFNs)
4.4.2.1. Interferons (IFNs) Market, 2018 - 2030 (USD Million)
4.4.3. Interleukins (ILs)
4.4.3.1. Interleukins (ILs) Market, 2018 - 2030 (USD Million)
4.4.4. Others
4.4.4.1. Others Market, 2018 - 2030 (USD Million)
4.5. Antibodies
4.5.1. Antibodies, 2018 - 2030 (USD Million)
4.6. Immune Checkpoint Proteins
4.6.1. Immune Checkpoint Proteins Market, 2018 - 2030 (USD Million)
4.7. Virus Antigens
4.7.1. Virus Antigens Market, 2018 - 2030 (USD Million)
4.8. Enzymes
4.8.1. Enzymes Market, 2018 - 2030 (USD Million)
4.8.2. Kinases
4.8.2.1. Kinases Market, 2018 - 2030 (USD Million)
4.8.3. Metabolic Enzymes
4.8.3.1. Metabolic Enzymes Market, 2018 - 2030 (USD Million)
4.8.4. Others
4.8.4.1. Others Market, 2018 - 2030 (USD Million)
4.9. Recombinant Regulatory Proteins
4.9.1. Recombinant Regulatory Proteins Market, 2018 - 2030 (USD Million)
4.10. Hormones
4.10.1. Hormones Market, 2018 - 2030 (USD Million)
4.11. Others
4.11.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 5. HOST CELL BUSINESS ANALYSIS
5.1. Host Cell Segment Dashboard
5.2. Research-grade Proteins Market: Host Cell Movement Analysis
5.3. Global Research-Grade Proteins Market Size & Trend Analysis, by Host Cell, 2018 to 2030 (USD Million)
5.4. Mammalian Cells
5.4.1. Mammalian Cells Market, 2018 - 2030 (USD Million)
5.5. Bacterial Cells
5.5.1. Bacterial Cells Market, 2018 - 2030 (USD Million)
5.6. Yeast & Fungi
5.6.1. Yeast & Fungi Market, 2018 - 2030 (USD Million)
5.7. Insect Cells
5.7.1. Insect Cells Market, 2018 - 2030 (USD Million)
5.8. Others
5.8.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 6. END USE BUSINESS ANALYSIS
6.1. End Use Segment Dashboard
6.2. Research-grade Proteins Market: End Use Movement Analysis
6.3. Global Research-Grade Proteins Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
6.4. Pharmaceutical & Biotechnology Companies
6.4.1. Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Million)
6.5. Academic & Research Institutes
6.5.1. Academic & Research Institutes Market, 2018 - 2030 (USD Million)
6.6. Others
6.6.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 7. REGIONAL BUSINESS ANALYSIS
7.1. Regional Dashboard
7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
7.3. North America
7.3.1. North America Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.3.2. U.S.
7.3.2.1. Key Country Dynamics
7.3.2.2. Competitive Scenario
7.3.2.3. U.S. Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.3.3. Canada
7.3.3.1. Key Country Dynamics
7.3.3.2. Competitive Scenario
7.3.3.3. Canada Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.4. Europe
7.4.1. Europe Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.4.2. UK
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. UK Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.4.3. Germany
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Germany Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.4.4. Spain
7.4.4.1. Key Country Dynamics
7.4.4.2. Competitive Scenario
7.4.4.3. Spain Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.4.5. France
7.4.5.1. Key Country Dynamics
7.4.5.2. Competitive Scenario
7.4.5.3. France Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.4.6. Italy
7.4.6.1. Key Country Dynamics
7.4.6.2. Competitive Scenario
7.4.6.3. Italy Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.4.7. Denmark
7.4.7.1. Key Country Dynamics
7.4.7.2. Competitive Scenario
7.4.7.3. Denmark Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.4.8. Sweden
7.4.8.1. Key Country Dynamics
7.4.8.2. Competitive Scenario
7.4.8.3. Sweden Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.4.9. Norway
7.4.9.1. Key Country Dynamics
7.4.9.2. Competitive Scenario
7.4.9.3. Norway Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Asia-Pacific Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.5.2. Japan
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Japan Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.5.3. China
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. China Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.5.4. India
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. India Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key Country Dynamics
7.5.5.2. Competitive Scenario
7.5.5.3. South Korea Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key Country Dynamics
7.5.6.2. Competitive Scenario
7.5.6.3. Thailand Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.5.7. Australia
7.5.7.1. Key Country Dynamics
7.5.7.2. Competitive Scenario
7.5.7.3. Australia Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.6. Latin America
7.6.1. Latin America Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.6.2. Brazil
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Brazil Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.6.3. Argentina
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Argentina Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.7. MEA
7.7.1. MEA Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.7.2. South Africa
7.7.2.1. Key Country Dynamics
7.7.2.2. Competitive Scenario
7.7.2.3. South Africa Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.7.3. Saudi Arabia
7.7.3.1. Key Country Dynamics
7.7.3.2. Competitive Scenario
7.7.3.3. Saudi Arabia Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.7.4. UAE
7.7.4.1. Key Country Dynamics
7.7.4.2. Competitive Scenario
7.7.4.3. UAE Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.7.5. Kuwait
7.7.5.1. Key Country Dynamics
7.7.5.2. Competitive Scenario
7.7.5.3. Kuwait Research-grade Proteins Market, 2018 - 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Position Analysis, 2024
8.4. Company Profiles/Listing
8.4.1. Thermo Fisher Scientific, Inc.
8.4.1.1. Company Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. Abcam Plc
8.4.2.1. Company Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Miltenyi Biotec
8.4.3.1. Company Overview
8.4.3.2. Product Benchmarking
8.4.3.3. Strategic Initiatives
8.4.4. GenScript
8.4.4.1. Company Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Bio-Techne
8.4.5.1. Company Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. Proteintech Group, Inc.
8.4.6.1. Company Overview
8.4.6.2. Product Benchmarking
8.4.6.3. Strategic Initiatives
8.4.7. ACROBiosystems
8.4.7.1. Company Overview
8.4.7.2. Product Benchmarking
8.4.7.3. Strategic Initiatives
8.4.8. Sino Biological, Inc.
8.4.8.1. Company Overview
8.4.8.2. Product Benchmarking
8.4.8.3. Strategic Initiatives
8.4.9. ProSpec-Tany TechnoGene Ltd.
8.4.9.1. Company Overview
8.4.9.2. Product Benchmarking
8.4.9.3. Strategic Initiatives
8.4.10. New England Biolabs
8.4.10.1. Company Overview
8.4.10.2. Product Benchmarking
8.4.10.3. Strategic Initiatives
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Product Segment
1.2.2. Host Cell Segment
1.2.3. End Use Segment
1.3. Research Assumptions
1.4. Information Procurement
1.4.1. Primary Research
1.5. Information or Data Analysis
1.6. Market Formulation & Validation
1.7. Market Model
1.8. Global Market: CAGR Calculation
1.9. Objectives
CHAPTER 2. RESEARCH-GRADE PROTEINS MARKET: EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. RESEARCH-GRADE PROTEINS MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.1.1. Increasing use of recombinant proteins in research activities
3.3.1.2. Growing research activities for drug discovery and precision medicine
3.3.1.3. Rising adoption of biologics & biosimilars
3.3.2. Market Restraint Analysis
3.3.2.1. Regulatory and safety concerns regarding protein production
3.3.2.2. Dearth of skilled personnel and expertise
3.4. Business Environment Analysis
3.4.1. PESTEL Analysis
3.4.2. Porter’s Five Forces Analysis
3.4.3. COVID-19 Impact Analysis
CHAPTER 4. PRODUCT BUSINESS ANALYSIS
4.1. Product Segment Dashboard
4.2. Research-grade Proteins Market: Product Movement Analysis
4.3. Global Research-Grade Proteins Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.4. Cytokines & Growth Factors
4.4.1. Cytokines & Growth Factors Market, 2018 - 2030 (USD Million)
4.4.2. Interferons (IFNs)
4.4.2.1. Interferons (IFNs) Market, 2018 - 2030 (USD Million)
4.4.3. Interleukins (ILs)
4.4.3.1. Interleukins (ILs) Market, 2018 - 2030 (USD Million)
4.4.4. Others
4.4.4.1. Others Market, 2018 - 2030 (USD Million)
4.5. Antibodies
4.5.1. Antibodies, 2018 - 2030 (USD Million)
4.6. Immune Checkpoint Proteins
4.6.1. Immune Checkpoint Proteins Market, 2018 - 2030 (USD Million)
4.7. Virus Antigens
4.7.1. Virus Antigens Market, 2018 - 2030 (USD Million)
4.8. Enzymes
4.8.1. Enzymes Market, 2018 - 2030 (USD Million)
4.8.2. Kinases
4.8.2.1. Kinases Market, 2018 - 2030 (USD Million)
4.8.3. Metabolic Enzymes
4.8.3.1. Metabolic Enzymes Market, 2018 - 2030 (USD Million)
4.8.4. Others
4.8.4.1. Others Market, 2018 - 2030 (USD Million)
4.9. Recombinant Regulatory Proteins
4.9.1. Recombinant Regulatory Proteins Market, 2018 - 2030 (USD Million)
4.10. Hormones
4.10.1. Hormones Market, 2018 - 2030 (USD Million)
4.11. Others
4.11.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 5. HOST CELL BUSINESS ANALYSIS
5.1. Host Cell Segment Dashboard
5.2. Research-grade Proteins Market: Host Cell Movement Analysis
5.3. Global Research-Grade Proteins Market Size & Trend Analysis, by Host Cell, 2018 to 2030 (USD Million)
5.4. Mammalian Cells
5.4.1. Mammalian Cells Market, 2018 - 2030 (USD Million)
5.5. Bacterial Cells
5.5.1. Bacterial Cells Market, 2018 - 2030 (USD Million)
5.6. Yeast & Fungi
5.6.1. Yeast & Fungi Market, 2018 - 2030 (USD Million)
5.7. Insect Cells
5.7.1. Insect Cells Market, 2018 - 2030 (USD Million)
5.8. Others
5.8.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 6. END USE BUSINESS ANALYSIS
6.1. End Use Segment Dashboard
6.2. Research-grade Proteins Market: End Use Movement Analysis
6.3. Global Research-Grade Proteins Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
6.4. Pharmaceutical & Biotechnology Companies
6.4.1. Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Million)
6.5. Academic & Research Institutes
6.5.1. Academic & Research Institutes Market, 2018 - 2030 (USD Million)
6.6. Others
6.6.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 7. REGIONAL BUSINESS ANALYSIS
7.1. Regional Dashboard
7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
7.3. North America
7.3.1. North America Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.3.2. U.S.
7.3.2.1. Key Country Dynamics
7.3.2.2. Competitive Scenario
7.3.2.3. U.S. Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.3.3. Canada
7.3.3.1. Key Country Dynamics
7.3.3.2. Competitive Scenario
7.3.3.3. Canada Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.4. Europe
7.4.1. Europe Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.4.2. UK
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. UK Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.4.3. Germany
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Germany Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.4.4. Spain
7.4.4.1. Key Country Dynamics
7.4.4.2. Competitive Scenario
7.4.4.3. Spain Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.4.5. France
7.4.5.1. Key Country Dynamics
7.4.5.2. Competitive Scenario
7.4.5.3. France Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.4.6. Italy
7.4.6.1. Key Country Dynamics
7.4.6.2. Competitive Scenario
7.4.6.3. Italy Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.4.7. Denmark
7.4.7.1. Key Country Dynamics
7.4.7.2. Competitive Scenario
7.4.7.3. Denmark Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.4.8. Sweden
7.4.8.1. Key Country Dynamics
7.4.8.2. Competitive Scenario
7.4.8.3. Sweden Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.4.9. Norway
7.4.9.1. Key Country Dynamics
7.4.9.2. Competitive Scenario
7.4.9.3. Norway Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Asia-Pacific Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.5.2. Japan
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Japan Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.5.3. China
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. China Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.5.4. India
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. India Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key Country Dynamics
7.5.5.2. Competitive Scenario
7.5.5.3. South Korea Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key Country Dynamics
7.5.6.2. Competitive Scenario
7.5.6.3. Thailand Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.5.7. Australia
7.5.7.1. Key Country Dynamics
7.5.7.2. Competitive Scenario
7.5.7.3. Australia Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.6. Latin America
7.6.1. Latin America Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.6.2. Brazil
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Brazil Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.6.3. Argentina
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Argentina Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.7. MEA
7.7.1. MEA Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.7.2. South Africa
7.7.2.1. Key Country Dynamics
7.7.2.2. Competitive Scenario
7.7.2.3. South Africa Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.7.3. Saudi Arabia
7.7.3.1. Key Country Dynamics
7.7.3.2. Competitive Scenario
7.7.3.3. Saudi Arabia Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.7.4. UAE
7.7.4.1. Key Country Dynamics
7.7.4.2. Competitive Scenario
7.7.4.3. UAE Research-grade Proteins Market, 2018 - 2030 (USD Million)
7.7.5. Kuwait
7.7.5.1. Key Country Dynamics
7.7.5.2. Competitive Scenario
7.7.5.3. Kuwait Research-grade Proteins Market, 2018 - 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Position Analysis, 2024
8.4. Company Profiles/Listing
8.4.1. Thermo Fisher Scientific, Inc.
8.4.1.1. Company Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. Abcam Plc
8.4.2.1. Company Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Miltenyi Biotec
8.4.3.1. Company Overview
8.4.3.2. Product Benchmarking
8.4.3.3. Strategic Initiatives
8.4.4. GenScript
8.4.4.1. Company Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Bio-Techne
8.4.5.1. Company Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. Proteintech Group, Inc.
8.4.6.1. Company Overview
8.4.6.2. Product Benchmarking
8.4.6.3. Strategic Initiatives
8.4.7. ACROBiosystems
8.4.7.1. Company Overview
8.4.7.2. Product Benchmarking
8.4.7.3. Strategic Initiatives
8.4.8. Sino Biological, Inc.
8.4.8.1. Company Overview
8.4.8.2. Product Benchmarking
8.4.8.3. Strategic Initiatives
8.4.9. ProSpec-Tany TechnoGene Ltd.
8.4.9.1. Company Overview
8.4.9.2. Product Benchmarking
8.4.9.3. Strategic Initiatives
8.4.10. New England Biolabs
8.4.10.1. Company Overview
8.4.10.2. Product Benchmarking
8.4.10.3. Strategic Initiatives
